Skip to main content

Year: 2023

VirTra Founder and Executive Chairman Bob Ferris Inducted into the National Center for Simulation’s Modeling & Simulation Hall of Fame

Founder and Executive Chairman, Bob FerrisFounder and Executive Chairman, Bob FerrisCHANDLER, Ariz., Oct. 31, 2023 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use of force training simulators, firearms training simulators for the law enforcement and military markets, today announces the induction of its Founder and Executive Chairman, Bob Ferris, into the National Center for Simulation (NCS) Modeling & Simulation (M&S) Hall of Fame. This prestigious recognition, bestowed upon Ferris for his groundbreaking work and continued thought leadership in the simulation industry, reflects VirTra’s legacy of innovation and its commitment to continually improving training effectiveness. Ferris was inducted alongside other 2023 inductees at a ceremony on October...

Continue reading

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U.S. financial markets on Monday, November 6, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 6th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing...

Continue reading

Esperion to Participate in Jefferies London Healthcare Conference

ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 14, 2023 at 3:00 AM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at...

Continue reading

IPG Photonics Announces Third Quarter 2023 Financial Results

 Weak Industrial Demand and Lower E-mobility Sales in China Negatively Impacted Results Gross Margin Improved to 44.1% Driven by Continued Focus on Manufacturing Costs and Efficiency MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) —   IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2023.    Three Months Ended September 30,       Nine Months Ended September 30,    (In millions, except per share data and percentages)     2023       2022     Change     2023       2022     ChangeRevenue   $ 301.4     $ 349.0     (14)%   $ 988.5     $ 1,096.0     (10)%Gross margin     44.1 %     43.1 %         43.2 %     45.1 %    Operating income   $ 55.7     $ 93.2     (40)%   $ 203.2     $ 258.0     (21)%Operating margin     18.5 %     26.7 %         20.6 %     23.5 %    Net...

Continue reading

Talkspace to Present at the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that Jon R. Cohen, M.D., CEO, and Jennifer Fulk, CFO, will participate in a fireside chat and host one-on-one investor meetings at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL, on November 29, 2023. The Company’s fireside chat will be at 3:50 pm ET. A webcast of the fireside chat at the 6th Annual Evercore ISI HealthCONx Conference will be available on the Talkspace Investor Relations Website: https://investors.talkspace.com/. To schedule a one-on-one meeting with Dr. Cohen and Ms. Fulk, please contact your Evercore ISI representative. About Talkspace Talkspace (Nasdaq: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through...

Continue reading

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The dosing phase of PRESent-3 follows a minimum 12-week observation period during which prospective baseline data of the subject’s disease status under their current therapy are collected to support regulatory review of the benefit and risk profile of SerpinPC. The Company began dosing subjects in the registrational PRESent-2 study for the treatment of hemophilia B without inhibitors in July 2023. SerpinPC is an investigational subcutaneously administered novel...

Continue reading

ZimVie Announces First U.S. Surgery with the 4.5mm Mobi-C® Cervical Disc

WESTMINSTER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the first patient in the United States has received the newly approved 4.5mm Mobi-C® Cervical Disc. Introduced in France in 2004, Mobi-C became the first cervical disc approved for one and two levels by the FDA in 2013. The smaller 4.5mm height Mobi-C implants, available in seven footprints to match patient anatomy, were approved by the FDA in August of this year. On October 30, 2023, Gregory D. Lopez, M.D., orthopaedic spine surgeon with Midwest Orthopaedics at Rush in Chicago, Illinois, implanted the first 4.5mm Mobi-C in the United States. “The 59-year-old patient presented with a significantly collapsed C5-6 disc, and the new lower profile Mobi-C implant allowed...

Continue reading

Golden Sky Continues to Expand the Semlin Porphyry-Style Target to 1.7 x 0.9 km, Rayfield Property, British Columbia

Figure 1Figure 1: The ~35,000-hectare Rayfield Cu-Au Property is located within the Quesnel Trough, British Columbia’s primary copper-producing belt.Figure 2Figure 2: The Semlin target zone is defined by a large 1.7 km x 0.9 km multi-element soil geochemical anomaly which may be outlining a buried porphyry system. The Rayfield target zone is highly prospective, with anomalous copper-in-soil values grading up to ~0.40%, and rock samples grading up to 0.63% Cu and 245 ppb Au. Numerous other target zones also exist across the extensive 35,000-hectare Rayfield Property.Figure 3Figure 3: Copper-in-soil assays values from the 2022/2023 soil sampling program, with overlapping Cu-Au-Zn-As multi-element geochemical signature outlined in dashed black outline. The mineralized system remains open.Figure 4Figure 4:...

Continue reading

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition of immune cell recruitment, shown in multiple models of inflammatory disease Demonstrates OMEGA platform’s ability to prospectively engineer programmable mRNA candidates to enable multiplexing for controlled epigenomic modulation CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International...

Continue reading

CMG Announces Partnership with ABB to Deliver Powerful New Technology for Carbon Capture and Storage (CCS)

ABB to integrate CMG simulation technology into CCS digital twin platform to reduce environmental and financial risks CALGARY, Alberta, Oct. 31, 2023 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) (TSX: CMG) is pleased to announce a partnership with global technology leader ABB to integrate CMG’s subsurface simulation technology into ABB’s digital twin platform for commercial carbon capture and storage (CCS) operations. The partnership aims to develop a new product in which ABB will use its Ability™ OPTIMAX® energy management system to integrate above ground digital twin technology with CMG’s subsurface modelling, providing a full ‘source to storage’ solution to support the successful operation of CCS projects. “This partnership brings together two powerful technologies to develop a solution to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.